Related Experiment Video

Updated: Apr 12, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure

João Pedro Ferreira1, Mário Santos1, José Carlos Oliveira1

  • 1Centro Hospitalar do Porto, Porto, Portugal.

Arquivos Brasileiros De Cardiologia
|May 21, 2015
PubMed
Abstract

Insights

Spironolactone treatment may reduce matrix metalloproteinase-2 (MMP2) levels in patients with acutely decompensated heart failure (ADHF). This suggests a potential therapeutic benefit for MMP2 modulation in ADHF management.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Matrix metalloproteinases (MMPs) are crucial for extracellular matrix remodeling and vascular repair.
  • Elevated MMP2 activity is observed in heart failure.
  • A decrease in MMPs correlates with successful treatment in acutely decompensated heart failure (ADHF).

Purpose of the Study:

  • To investigate the effect of spironolactone on MMP2 levels in patients with ADHF.
  • To assess spironolactone's influence on MMP2 as a potential biomarker in heart failure.

Main Methods:

  • Secondary analysis of a prospective interventional study with 100 ADHF patients.
  • Fifty patients received spironolactone (100 mg/day) plus standard therapy; 50 received standard therapy alone (control).
  • MMP2 levels, NT-pro BNP, and weight were measured at baseline and day 3.

Main Results:

  • The spironolactone group was younger with lower creatinine and urea levels.
  • A trend towards a greater decrease in MMP2 levels was observed in the spironolactone group (p=0.06).
  • Greater reductions in NT-pro BNP and weight were also noted in the spironolactone group.

Conclusions:

  • MMP2 levels are elevated in ADHF.
  • Spironolactone treatment may lead to a more significant reduction in MMP2 levels in ADHF patients.
  • Further research is warranted to confirm MMP2 as a therapeutic target in heart failure.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K